Licensing status

Publication and contact information

Drug platforms

mAb antagonists against glucose-dependent insulinotropic polypeptide receptor (GIPR)

mAb antagonists against GIPR could be useful as tools to develop improved inhibitors and study receptor function in human disease. Highly specific and potent GIPR antagonists with long in vivo half-lives have not been previously reported. Phage and ribosome display libraries were used to generate Gipg013, which selectively antagonized human GIPR with an in vitro Kd value of 7 nM. In mice, Gipg013 had a half-life of about 10 days. MedImmune LLC did not disclose next steps, which could include evaluating the mAb antagonists in disease models.

SciBX 6(24); doi:10.1038/scibx.2013.611
Published online June 20, 2013

Patent status undisclosed; licensing status not applicable

Ravn, P. et al. J. Biol. Chem.; published online May 20, 2013;
Contact: Peter Ravn, MedImmune LLC, Cambridge, U.K.